CA2539032A1 — Glucopyranosyloxy-pirazoles, drugs containing said compounds the use and production method thereof
Assigned to Boehringer Ingelheim International GmbH · Expires 2005-03-10 · 21y expired
What this patent protects
The invention relates to glucopyranosyloxy-pirazoles of formula (I), wherein R1 to R6 and R7a, R7b and R7c are defined in the claim 1, to the tautomers, stereoisomers, mixtures and the salts thereof, in particular the salts which are physiologically compatible with inorganic or o…
USPTO Abstract
The invention relates to glucopyranosyloxy-pirazoles of formula (I), wherein R1 to R6 and R7a, R7b and R7c are defined in the claim 1, to the tautomers, stereoisomers, mixtures and the salts thereof, in particular the salts which are physiologically compatible with inorganic or organic acids and exhibit interesting pharmacological properties, in particular inhibitor effect on a sodium-dependent SGLT glucose cotransporter. The use of the inventive compounds for treating diseases, in particular metabolic diseases such as diabetes and the production thereof are also disclosed.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.